More study data available!
Data has been uploaded for 4 studies including:
- Clinical trials:
- CAVD 514 (Nussenzweig Ph I) evaluates increasing doses of 10-1074 (3, 10, 30 mg/kg) in HIV infected and uninfected subjects
- CAVD 583 (Nussenzweig Ph I) evaluates a combination of 3BNC117 and 10-1074 given in single (10 mg/kg) or multiple timepoint (3 and 10 mg/kg) regimens
- HVTN 505 (Hammer Ph IIb) evaluates a VRC-HIVDNA016-00-VP (DNA) and VRCHIVADV014-00-VP (rAd5) combination regimen
- Pre-clinical studies:
- CAVD 432 (Pulendran NHP) study compares envelope-specific antibody responses across groups receiving different adjuvants combined with HIV-1 gp140 trimer (1086C).
Click on the study page links below for Protocol Team reports, data summaries, and more details about the studies.
Data was uploaded for the following studies:
|
Name & Description |
Data Added |
Type |
PI |
Strategy |
|
CAVD 432 is a non-human primate study of protein and adjuvant regimens |
BAMA, NAB |
Pre-Clinical NHP |
Bali Pulendran |
Protein and peptide vaccines |
|
CAVD 514 (Protocol MCA-0885) is a Phase 1 open-label, dose escalation clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in HIV-infected and HIV-uninfected individuals |
PK MAB |
Phase I |
Michel Nussenzweig |
Prophylactic neutralizing Ab |
|
CAVD 583 (Protocol YCO-899) is a Phase 1 clinical trial evaluating safety and pharmacokinetics of the highly neutralizing anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 in healthy HIV-uninfected participants |
PK MAB |
Phase I |
Michel Nussenzweig |
Prophylactic neutralizing Ab |
|
HVTN 505 is a Phase IIb clinical trial to evaluate the safety and immunogenicity of VRC-HIVDNA016-00-VP (DNA) and VRCHIVADV014-00-VP (rAd5) |
Non-integrated datasets: ADCP, Fc Array, supplemental demographics Previously posted: BAMA, NAB, ICS |
Phase IIb |
Scott Hammer |
Combo: DNA and vector vaccines |